Free Trial
LON:BVXP

Bioventix 10/28/2024 Earnings Report

Bioventix logo
GBX 2,770 +45.00 (+1.65%)
As of 07/18/2025 11:38 AM Eastern

Bioventix EPS Results

Actual EPS
GBX 155.12
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioventix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bioventix Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Bioventix Earnings Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
3 UK Dividend Stocks Offering Yields Up To 7.2%
3 top AIM stocks to consider buying before they recover
See More Bioventix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioventix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioventix and other key companies, straight to your email.

About Bioventix

Bioventix (LON:BVXP) creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.

View Bioventix Profile

More Earnings Resources from MarketBeat